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Abstract 
The COVID-19 pandemic has currently overtaken every other health issue throughout the world. There are numerous 
ways in which this will impact existing public health issues. Here we reflect on the interactions between COVID-19 
and tuberculosis (TB), which still ranks as the leading cause of death from a single infectious disease globally. There 
may be grave consequences for existing and undiagnosed TB patients globally, particularly in low and middle income 
countries (LMICs) where TB is endemic and health services poorly equipped. TB control programmes will be strained 
due to diversion of resources, and an inevitable loss of health system focus, such that some activities cannot or will 
not be prioritised. This is likely to lead to a reduction in quality of TB care and worse outcomes. Further, TB patients 
often have underlying co-morbidities and lung damage that may make them prone to more severe COVID-19. The 
symptoms of TB and COVID-19 can be similar, with for example cough and fever. Not only can this create diagnos-
tic confusion, but it could worsen the stigmatization of TB patients especially in LMICs, given the fear of COVID-19. 
Children with TB are a vulnerable group especially likely to suffer as part of the “collateral damage”. There will be a 
confounding of symptoms and epidemiological data through co-infection, as happens already with TB–HIV, and this 
will require unpicking. Lessons for COVID-19 could be learned from the vast experience of running global TB control 
programmes, while the astonishingly rapid and relatively well co-ordinated response to COVID-19 demonstrates how 
existing programmes could be significantly improved.
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Background
Every year, March 24th is celebrated as Annual World TB 
Day. This is usually acknowledged across the world by a 
wide range of activities, to highlight the unsettling fact 
that Mycobacterium tuberculosis, a human-specific path-
ogen, is still a scourge after millennia of coexistence. It 
has recently reclaimed top spot as the infectious disease 
that kills more people in the world than any other infec-
tious pathogen.
This year, however, its show was stolen by a newly-
emerging pandemic caused by a novel pathogen, Severe 
Acute Respiratory Syndrome Coronavirus-2 (SARS-
CoV-2), which has jumped from animals to humans and 
causes the disease named COVID-19—a flu-like disease 
characterised by severe acute respiratory distress in 
its most severe form. By the first week of April 2020, a 
million cases of COVID-19 disease had been diagnosed 
worldwide, including at least 50,000 deaths since the 
beginning of the epidemic in January 2020. World TB 
Day itself was eclipsed, with events cancelled throughout 
the world, including our own annual London symposium 
[1].
In an extraordinarily short time, COVID-
19 has supplanted everything—normal activity, 
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non-SARS-CoV-2-related discussion, research, clinical 
trials, etc. It can seem as if things that were previously 
hugely significant issues are no longer important.
So, what about TB when COVID-19 is so front-and-
centre globally? Clearly TB has not disappeared, but 
does anyone still care? And if so, are we able to do more 
than watch as an existing global health problem becomes 
increasingly neglected—leading to predictable outcomes? 
On the plus side, with such a long history of intense 
research and infectious disease management, can TB 
teach the world anything about how we should deal with 
COVID-19?
Tuberculosis remains a global health emergency and 
needs our attention more than ever, given that significant 
resources are now being diverted to COVID-19 manage-
ment. To lose sight of the unfinished business of tubercu-
losis control will jeopardise important milestones, gains 
and ambitions, and we believe that now more than ever is 
the time to care about TB in adults and children1. In this 
manuscript, we cover areas of particular concern for both 
epidemics facing us today. This reflection was developed 
from a video conversation held by the participants on 20 
March 2020 and posted online following the cancellation 
of our World TB Day 2020 event [2] .
Scope
We discussed issues of how COVID-19 would affect con-
trol programmes: prioritisation of services, availability of 
drugs, the effect on hard-to-reach and low-income com-
munities and the role of stigmatisation, how paediatric 
TB disease might be affected, the possibility of increased 
disease transmission or disease susceptibility, and the 
problems caused by likely co-morbidity. We thought it 
important to look at the situations in both high-income 
countries (HICs) and low and middle-income countries 
(LMICs), and we used the UK and Africa as exemplars 
with which we are most familiar. We also reviewed how 
control programmes for each disease could learn from 
each other.
We are of course not the only people reviewing and 
comparing these two pandemics, and we acknowledge 
the contributions by Wingfield et  al. [3] who discussed 
the negative effect of COVID-19 on TB patients and con-
trol programmes, and The Union supported by TB Alert 
[4, 5] who actively compared and contrast the two dis-
eases, and focused on ways in which TB expertise can be 
useful for COVID-19 control.
The situation in the UK and Africa
The UK
As an example of an HIC, the UK has a significant TB 
problem with approximately 4500 new cases a year, par-
ticularly in London [6]. There is a specific integrated TB 
control programme with allocated staff managing all 
aspects of diagnosis, treatment, contact tracing, outbreak 
investigation, latent disease, dialogue with communi-
ties, and linking to other relevant charities and organiza-
tions. In recent years, the numbers of cases have fallen, 
and multiple and extensively drug-resistant cases have 
been successfully treated. This TB control programme 
lies within a single National Health Service, administered 
through separate trusts, with healthcare free at the point 
of care for all citizens.
At the time of our video discussion, the UK was in the 
middle of the first wave of COVID-19, with the popula-
tion under lockdown, number of cases and deaths still 
rising—putting a tremendous strain on the NHS as it 
struggled to cope with this, and much of normal clini-
cal practice put on hold. London was the UK’s epicentre. 
Governmental loans to businesses and freelance work-
ers, and paid sick leave in a high proportion of cases, was 
put in place to minimise short-term economic damage. 
Working from home was encouraged for many through a 
good internet structure.
Africa
Africa has a much greater TB burden. In 2018, Africa had 
an estimated 24% of the 10 million global incident cases 
of TB and the region also has the smallest rate of decline 
of TB globally [7]. Although every country within Africa 
will have a different health system, they are limited and 
quality of TB care is sub-optimal. A 13-country patient-
pathways analysis that included six African countries 
with the highest TB burden on the continent found that 
less than 50% of estimated TB patients had documented 
treatment success [8]. Also, a cascade of TB patient care 
analysis in South Africa reported that only 53% of TB 
patients in South Africa were diagnosed and successfully 
treated [9].
By 1st April, the COVID-19 pandemic had started in 
Africa, with 3766 cases and 95 deaths [10]. A large rise in 
cases of COVID-19 was expected as countries ramped up 
their testing and diagnostic capacity for COVID-19 [11] 
in the context of already stretched and poorly-resourced 
health care systems.
How will COVID‑19 impact on TB control in the UK?
It’s already apparent that there will be a need to priori-
tise the care that TB services can deliver. TB control will 
focus on TB disease rather than prevention (such as the 
management of latent, non-transmissible TB infection). 
1 This has been subsequently modelled by the Stop TB Partnership to sug-
gest that the impact of 2 months of lockdown and 2 months recovery will add 
an excess 1.8 million cases of TB disease over the next 5  years http://www.
stopt b.org/asset s/docum ents/news/Model ing%20Rep ort_1%20May %20202 
0_FINAL .pdf.
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This arises in part because of a TB workforce being re-
directed to manage COVID-19, others being off sick or 
self-isolating (up to 30% of healthcare staff); and the con-
cern that too much social contact within a clinic is likely 
to result in more viral transmission. The need to reduce 
contact with patients who see their TB service as a source 
of both social and medical support may result in reduced 
adherence and worse outcomes. This will affect those 
who are least able to self-care—in other words the very 
people who most need TB services.
A potential unintended consequence of the UK and 
many other Government’s promotion and enforcement 
of isolation is that socially-disadvantaged and home-
less populations may be more likely to come together in 
hostels or other settings and hence increase their risk of 
acquiring and passing on infection. They are also perhaps 
less able to protect themselves from contact transmission 
by regular hand washing and use of sanitizers. In house-
holds who are self-isolating, a coughing adult may have a 
viral infection, though could have TB that is then inad-
vertently passed on to other family members.
Pre-COVID-19 and Brexit, there were regular anti-TB 
therapy stock-outs. This is likely to get worse as supply 
chains become harder to sustain during a time of pro-
longed infection, illness and economic shut down. As 
a result, not only will TB services have to modify treat-
ment regimens in line with what drugs are available, but 
there will also be errors in prescribing—leading to more 
adverse effects and treatment failures. These are issues 
that every high income country affected by COVID-19 
faces.
How is COVID‑19 going to impact on TB control 
in Africa?
One of the cardinal objectives of the WHO’s End TB 
Strategy [12], which proposes the target of ending the TB 
epidemic in the next 15  years, is the provision of high-
quality and patient-centred care for TB patients based 
on the their human rights [13]. This very ambitious tar-
get requires sustained political and financial commit-
ment from African countries toward the provision of 
basic essential universal health care, and specifically for 
TB diagnostic, prevention and treatment services. How-
ever, the studies cited earlier suggest that, even prior to 
the onset of the COVID-19 pandemic, the quality of TB 
care in Africa is sub-optimal. COVID-19 will potentially 
worsen patient care and TB control efforts in Africa, 
given the likely negative impact of the pandemic at the 
macroeconomic, health system and individual levels in 
Africa.
COVID-19 is expected to result in a global economic 
recession in 2020 with the economic downturn particu-
larly worse for the emerging markets and low-income 
countries, as recently communicated by the International 
Monetary Fund [14]. Without gainsaying, the impact 
of the global economic recession will be worse on the 
LMICs of Africa—many of which were either in border-
line or full economic recession prior to the coronavirus 
pandemic.
While HICs are now releasing economic stimulus pack-
ages, this will be practically impossible in African LMICs, 
who often depend on donor funds and natural resources 
from extractive industries. As these countries are now 
setting up and/or ramping-up their COVID-19 responses 
in the midst of a global economic downturn, we have 
already seen the diversion of political will, scarce finan-
cial and the limited human resources in the hitherto weak 
health system to the COVID-19 responses. As an exam-
ple, Nigeria that has the largest burden of TB in Africa 
and is one of the 30 high TB burden countries globally 
recently announced that 300 GeneXpert machines in the 
country will be diverted to efforts to scale-up COVID-19 
diagnosis [15]. This will definitely have a huge negative 
impact on basic and essential TB control efforts, includ-
ing routine diagnosis of TB cases, treatment monitoring 
by direct observation, provision of TB preventive ther-
apy, and contact tracing among others.
Tuberculosis in Africa is a disease of poverty as in all 
LMICs, most often afflicting the poorest people in the 
society who also have the least access to basic health care. 
We also know that socio-economic circumstances are a 
crucial determinant of health outcomes, in particular for 
people with tuberculosis. Many of the socioeconomic 
and behavioural factors that could enhance transmis-
sion of coronavirus in Africa are also the recognised fac-
tors that enhance transmission of M. tuberculosis. While 
patients with chronic cough might hesitate to seek care 
due to the ‘new’ stigma and fear associated with COVID-
19, they are very likely going to meet an unprepared and 
overwhelmed health system when, or if, they do. On the 
other hand, the interventions proposed to “flatten the 
curve” in COVID-19 responses e.g. physical distancing, 
regular handwashing, whole community lockdowns, etc. 
are going to be disproportionately more challenging for 
the poorest who most often live in overcrowded condi-
tions, with no or limited access to drinking water, and 
earn meagre incomes from daily wages. Furthermore, 
very little is known about the pathobiological mecha-
nisms of the COVID-19 caused by the novel SARS-CoV-2 
especially in populations in Africa with a relatively higher 
prevalence of HIV infection, TB, anaemia and malnutri-
tion, as well as in patients with significant post-TB lung 
damage.
Taken together, it is clear that the impact of COVID-19 
in Africa is going to be disproportionately worse on the 
very poor and the least-advantaged people, who already 
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bear the largest burden of both communicable and non-
communicable diseases, and also have the least access to 
basic healthcare. These will include many undiagnosed 
and current TB patients who are, as a result, very likely to 
have worse outcomes from their TB.
The likely impact of COVID‑19 on children with TB
Amongst the 1.5 million annual deaths from TB, an esti-
mated 205,000 occur in children with the majority occur-
ring in resource-poor settings [7]. Child survival from TB 
depends on timely diagnosis, prompt initiation of treat-
ment, community and health systems support for con-
tinuous availability of child friendly medication as well as 
prevention of transmission from sputum-smear positive 
index cases-usually adults-to vulnerable young children 
in households.
These important elements of the cascade of care are at 
stake at a time when resources will be focused on pro-
viding care for individuals affected by COVID-19. The 
diagnosis of childhood TB is not only made at dedicated 
clinics of National TB control programs but equally in 
generic child health clinics and hospital wards. Many of 
these facilities will be closed or overwhelmed with other 
tasks, and as a result diagnostic opportunity in children 
will be missed. The majority of children in LMIC are not 
seen by dedicated paediatric specialists, and many gen-
eral physicians and nurses usually available for their care 
will be seconded to dealing with adult patients affected 
by severe respiratory symptoms of COVID-19 instead.
Available specialist expertise in respiratory medicine 
switched to diagnosing and treating this new viral dis-
ease, which does not appear generally to have similarly 
severe manifestations in children compared to adults. 
Hence it will be assumed that children will cope better 
and do not need similar attention from the health ser-
vices during the COVID-19 pandemic. We are already 
witnessing this trend in HIC where routine clinics are 
cancelled and paediatric intensive care beds are handed 
over to adult services. Laboratories are likely to be over-
whelmed with analyses of respiratory specimens sent for 
COVID-19 rather than M. tuberculosis or other patho-
gens, and once the eagerly anticipated Xpert cartridges 
for COVID-19 are rolled out it is easy to imagine that 
GeneXpert platforms will be seconded for COVID-19 
diagnostics.
These issues are not specific for childhood TB as 
adult TB services are likely to be similarly affected. 
However, the timely diagnosis of TB in children is even 
more essential to prevent deaths. Families are reluctant 
to bring unwell children to the hospitals for investiga-
tion as everyone is discouraged from using health ser-
vices at this stage, unless severely unwell. Apart from 
TB meningitis, TB rarely presents as an acute, severe 
illness in children but progresses silently until tipping 
points are reached. Such subtle presentations are likely 
to be missed if children cannot be reviewed regularly. 
Given the overlapping presentations of TB and pneu-
monia in children in the first place, many children are 
initially placed on a trial of antibiotics but ought to be 
reviewed in a timely fashion. This does not happen with 
severely-stretched health services.
Another important part of services for children is the 
provision of preventive therapy (IPT) for TB infection 
in the community, which requires resources to contact 
trace, screen and eventually implement drug therapy. 
These services are rudimentary in LMICs at the best of 
times. IPT works, and given that the under 5 year olds 
are particularly at risk of progressing to TB disease in 
its absence, the number of cases of childhood TB will 
most likely rise as a consequence. Whether such figures 
can even be captured when services are near to break-
ing-point remains to be seen.
As most TB in young children is acquired in their 
own household, social distancing measures that keep 
a family together for long periods of time are likely to 
result in more exposure of children to infectious TB 
index cases. Contact screening for COVID-19 should 
therefore include questions about TB in the house-
hold in order to protect young children from additional 
risks.
Stigmatisation
Tuberculosis stigmatisation is a problem in many set-
tings, though more so in LMICs. It is likely to rise and 
be confounded by COVID-19. Stigma is associated 
with fear, and fear of COVID-19 will increase. This has 
already been seen in the cases primarily imported into 
Africa—with stigmatization being directed not only 
at the affected patients but also their carers and fam-
ily. This applies equally to healthcare workers who are 
likely to be managing both COVID-19 and TB.
The 2020 World TB Day had an emphasis on de-
stigmatizing TB, but we should be de-stigmatizing any 
infectious disease. People do not go around spreading 
disease deliberately within their communities. As such, 
there is the need for stronger community engagement, 
including families and community-based groups being 
enabled to act as advocates.
The symptoms of TB and COVID-19 can be simi-
lar, with for example cough, fever, breathlessness and 
malaise being common in both. Not only can this cre-
ate diagnostic confusion, but TB patients who are 
already stigmatized for coughing will be even more 
likely to be viewed with concern in LMICs, given the 
fear of COVID-19. This could result in people being 
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afraid to present to healthcare services when they have 
such symptoms that in fact result from TB.
What can we learn from interactions 
between COVID‑19 and TB disease?
In a minority of patients, mainly elderly adults and/or 
those with underlying comorbidities, COVID-19 leads to 
severe pneumonitis and possibly long-term lung damage. 
We have much to learn about the long-term effect of this 
virus on lung function. The clinical presentation of lung 
disease in TB can be different, yet important interactions 
between the two diseases can be anticipated and need to 
be understood. To be diagnosed with COVID-19 does 
not exclude underlying TB, and in TB endemic settings 
particular attention should now be paid to this.
There are no data currently to inform us of the out-
comes of co-infection, or that of COVID-19 in known TB 
patients. This information will emerge once the COVID-
19 pandemic reaches the TB endemic areas of Africa and 
Asia. Data on long term sequelae for lung health in TB 
patients are sparse, and going forward, research studies 
(both laboratory and clinic-based) need to take COVID-
19 into account as a possible co-factor in the interpreta-
tion of their results. Post-TB lung damage was an area 
that was until recently largely ignored. Hopefully this will 
now change given the potential for such patients to do 
worse with COVID-19 disease.
Similar considerations need to be given to COVID-19/
HIV co-infections or underlying TB/HIV co-infection. 
There needs to be a particular emphasis on possible 
drug-drug interactions in individuals on medication for 
TB and/or HIV, who also may be using additional anti-
virals and immune-modulating agents which show prom-
ise against COVID-19.
What lessons for control can TB and COVID‑19 
learn from each other?
The impact of COVID-19 on populations and health sys-
tems in Africa will be very broad. The response, therefore, 
needs to be equally comprehensive and long term, rather 
than focused on just COVID-19. Countries in Africa will 
no doubt need help from the rich nations to mount a 
robust, sustained and regional response. Therefore, “it is 
time” for African countries to galvanize global attention 
and advocacy right now to substantially increase their 
investments toward the provision of universal health 
care, and to comprehensively strengthen their national 
health systems, with a particular focus on the primary 
health care and provision of essential diagnostics to the 
poorest and the least advantaged in society. This should 
be a wake-up call for countries in Africa to substantially 
increase their investments in health.
Tuberculosis control has only been possible through 
robust and consistent diagnosis, accompanied by con-
tact tracing, including in households. This has also 
been implemented in the early stages of the COVID-19 
pandemic in many—but by no means all—countries in 
order to minimise spread. The associated social distanc-
ing has helped to “flatten the curve” in China, South 
Korea and will hopefully be successful in all of the set-
tings where it is currently followed. Much depends on 
it right now. The COVID-19 pandemic reminds us of 
the importance of this approach to TB too—with pre-
vention being better than cure.
Community engagement has proven essential in 
TB control to address stigma, which has already been 
associated with COVID-19. Mitigation strategies that 
proved to be successful in TB might also assist in the 
community control of COVID-19 although the infec-
tion dynamics are very different.
The incredibly rapid and fruitful interactions of the 
scientific community to address the COVID-19 epi-
demic show what can be done when an emergency 
arises and scientists are focused and work together, 
with serious research funds being provided over a short 
time frame. It is encouraging to see the many new ini-
tiatives that have already arisen from the COVID-19 
pandemic, be it in modelling, artificial intelligence for 
clinical algorithms to predict disease severity, inter-
national clinical trial platforms, or drug and vaccine 
developments.
Neither COVID-19 nor TB respect geographical or 
scientific borders. Lessons learnt from this emergency 
need to be applied to other infectious diseases of global 
importance, including TB, where a similar emphasis 
on clinical and research activity would no doubt have 
a very large impact. Without it, we will never control 
TB. One positive from the COVID-19 pandemic may 
be that the world becomes more aware of the need to 
control and eliminate infections through sustained and 
joined-up working. Let’s keep the momentum going 
and not forget TB!
Conclusions
Tuberculosis is just one of many areas in global pub-
lic health that will be sidelined and adversely affected 
by the COVID-19 pandemic. It is important to start 
thinking critically about these effects, and develop 
comprehensive mitigation plans where possible. If not 
addressed, the 10 million incident TB cases and > 1 
million deaths from TB that occur annually worldwide 
will increase, with the negative impact being worst in 
LMICs. A positive aspect to these two pandemics col-
liding is that people—communities, public health 
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professionals and policy makers—can learn from each 
other. Perhaps we can look forward to a time when 
infectious diseases are taken even more seriously and 
the link between infectious disease and poverty is fur-
ther recognised such that increased investment in their 
control results in societal structural changes that ben-
efit all.
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